Agenus Inc. AGEN
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +107.96%
- 1 year
- +64.48%
- Open
- 6.85
- Prev close
- 6.84
- Mkt cap
- 294.91M
- Vol
- 595.55K
- Avg vol
- 1.07M
- EPS
- 2.42
- P/E
- 2.70
- Div yield
- 0.00%
More statistics
- Low
- 6.43
- High
- 6.86
- Forward P/E
- -0.28
- Beta
- 1.39
- Short ratio
- 4.16
- Inst. own
- 37.10%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.62
- 200-d avg
- 8.13
- 1y target
- 8.00
News
13 hours ago businesswire.com
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #IO--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice…
1 day ago businesswire.com
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the…
-
3 weeks ago benzinga.com
Agenus Receives Marketion Authorization From Armenia For Botvymo To Treat Adult Patients With Microsatellite Stable Metastatic Colorectal Cancer
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo®…
-
4 weeks ago benzinga.com
Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients
Survival estimate remained at 48% between years two and three, extending evidence of durable benefitResults observed in heavily pretreated, difficult-to-treat population that received a median of…
-
1 month ago benzinga.com
Agenus To Present Research On Botensilimab, Fc-Enhanced Multifunctional Anti-CTLA-4 Antibody, In Combination With Balstilimab, Anti-PD-1 Antibody, At SITC 2026
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody,…
1 month ago benzinga.com
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
-
1 month ago benzinga.com
Rodman & Renshaw Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $19
Rodman & Renshaw analyst Michael King initiates coverage on Agenus (NASDAQ:AGEN) with a Buy rating and announces Price Target of $19.
-
1 month ago benzinga.com
Chardan Capital Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $40
Chardan Capital analyst Andreas Argyrides initiates coverage on Agenus (NASDAQ:AGEN) with a Buy rating and announces Price Target of $40.
-
2 months ago benzinga.com
Agenus’ NEST Phase 2 Results Published In Clinical Cancer Research, No Colorectal Cancer Recurrences Observed At Updated Median Follow-Up Of 32.2 Months In NEST-1 And 23.5 Months In NEST-2 In pMMR/MSS Tumors, Neoadjuvant BOT+BAL Achieved 59% Pathologic Response, Including 41% Major Pathologic Response And 32% Pathologic Complete Response
No colorectal cancer recurrences observed at updated median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2In pMMR/MSS tumors, neoadjuvant BOT+BAL achieved 59% pathologic response,…
2 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
2 months ago benzinga.com
Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures mixed, Nasdaq 100 up 0.1%. Coty Inc (COTY) shares down 7.7% after reporting losses in Q4 and exit of Gucci Beauty license.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Agenus, Lowers Price Target to $25
HC Wainwright & Co. analyst Emily Bodnar maintains Agenus (NASDAQ:AGEN) with a Buy and lowers the price target from $30 to $25.
-
2 months ago benzinga.com
Agenus Q2 Sales $34.500M Beat $34.000M Estimate
Agenus (NASDAQ:AGEN) reported quarterly sales of $34.500 million which beat the analyst consensus estimate of $34.000 million by 1.47 percent. This is a 34.24 percent increase over sales of $25.700…
-
3 months ago benzinga.com
B. Riley Securities Maintains Buy on Agenus, Raises Price Target to $14
B. Riley Securities analyst Mayank Mamtani maintains Agenus (NASDAQ:AGEN) with a Buy and raises the price target from $8 to $14.
3 months ago benzinga.com
Why Is Agenus Stock Falling on Tuesday?
Agenus Inc. (AGEN) stock experiences profit-taking on Tuesday after a 111% surge. Discover the latest clinical data and analyst updates.
3 months ago benzinga.com
Stock Market Today: Dow, S&P 500, Nasdaq 100 Futures Rise on Better-Than-Expected CPI Data—Tower Semiconductor, Twin Vee, JPMorgan In Focus (UPDATED)
U.S. stock futures were mixed on Tuesday, as the Nasdaq 100 index advanced, while the Dow Jones and S&P 500 indices fell.
3 months ago benzinga.com
Oracle, Twin Vee PowerCats, Agenus, Micron Technology and SanDisk: Why These 5 Stocks Are on Investors' Radars Today
ORCL, VEEE, AGEN, MU, SNDK were among the stocks seen trending on Monday, July 13, 2026.
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million. Q32 Bio (NASDAQ:QTTB) stock rose…
3 months ago benzinga.com
Crude Oil Surges Over 5%; Twin Vee Powercats Shares Jump
US stocks dip, Nasdaq falls 1%. Dow down 0.34%. Energy shares up 2.1%, tech down 1.2%. Micron Tech drops 5%. Commodities mixed. European and Asian markets close mixed.
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Agenus, Raises Price Target to $30
HC Wainwright & Co. analyst Emily Bodnar maintains Agenus (NASDAQ:AGEN) with a Buy and raises the price target from $23 to $30.
3 months ago benzinga.com
Why Is Agenus Stock Gaining Monday?
Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M financing deal.
3 months ago benzinga.com
Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN
Agenus stock surged 100%, after the biotech secured up to $340 million in fresh capital, extended its cash runway, shelving the Phase 3 BATTMAN trial while doubling down on ROBBIN.
3 months ago benzinga.com
US Stocks Mixed; Dow Gains Over 100 Points
US stocks mixed, Dow up 100 points. Energy up 2.1%, tech down 1.1%. LogProstyle Inc shares rise on earnings. Oil up 3.9%, gold down 1%.
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-market session. The company's market cap stands at $25.1 million. Q32 Bio (NASDAQ:QTTB) stock rose 65.92% to…
-
3 months ago benzinga.com
Market-Moving News for July 13th
QTTB: 82% | Q32 Bio shares are trading higher after the company it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial on Monday, July 13, 2026. AGEN: 36% |…
-
3 months ago benzinga.com
Agenus To Raise $85M To Fund Colon Cancer Drug Trial, Financing Could Reach $340M If Warrants Are Exercised
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in…
-
4 months ago benzinga.com
Agenus Presents 3-Yr Landmark Phase 1b Data From Fully Enrolled C-800-01 Cohort Evaluating Botensilimab Plus Balstilimab In Patients With Refractory MSS mCRC Without Active Liver Metastases At ESMO GI 2026
Fully enrolled 123-patient Phase 1b cohort demonstrated 21.2-month median overall survival, 33% three-year overall survival, and a survival curve plateau beyond two yearsData presented in a heavily…
-
4 months ago benzinga.com
Agenus To Present 3-Yr Survival Data From Phase 1b C-800-01 Study Of Botensilimab Plus Balstilimab In Patients With Microsatellite Stable mCRC Without Active Liver Metastases At ESMO GI 2026
Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b studyAgenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that three-year…
-
5 months ago benzinga.com
Agenus Reports Durable Survival And Deep Responses With Botensilimab Plus Balstilimab In Heavily Pretreated Checkpoint-Resistant Melanoma, Including 16.6-Month Median OS and 42% Two-Year Survival
First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resisted prior checkpoint therapy and who had poor-risk disease featuresIn the overall BOT+BAL treated…
-
5 months ago benzinga.com
Agenus' Noetik TARIO-2 AI Model Identifies Tumor Microenvironment Signature Predicting 64% Response Rate And Markedly Improved Survival In MSS Metastatic Colorectal Cancer Treated With Botensilimab Plus Balstilimab
Noetik's TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated patients and identified spatial tumor microenvironment patterns associated with response and survivalIn a…
-
5 months ago benzinga.com
Agenus Announces Publication Of Phase 1b Data Evaluating Botensilimab In Combination With Balstilimab In Patients With Treatment-Refractory HCC
Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapyMedian overall survival of 12.3 months in a heavily pretreated population…
-
6 months ago benzinga.com
Agenus Announces Phase II Data Showing Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab And agenT-797 in PD-1 Refractory Gastroesophageal Cancer; The Study Did Not Meet Its Primary Endpoint Of ORR
First study combining botensilimab (BOT) and balstilimab (BAL) with agenT-797 in gastroesophageal cancer shows disease control rate (DCR) of 77% in patients and long-term survival beyond 20 months in…
-
7 months ago benzinga.com
Agenus Announces First Patient Enrolled In Global Phase 3 BATTMAN Trial
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of…
-
7 months ago benzinga.com
Agenus To Present Chemo-Sparing BOT+BAL Immunotherapy Data In 1L MSS Colorectal Cancer At AACR 2026
A novel, chemo-sparing strategy (BBoPCO): introducing BOT+BAL in 1L MSS mCRC to extend survival and reduce use of cytotoxic chemotherapyAgenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today…
-
7 months ago benzinga.com
Earnings Scheduled For March 16, 2026
Earnings Scheduled For March 16, 2026
-
7 months ago benzinga.com
Agenus Triggers First $20M Contingent Payment Under Prior Collaboration Deal With Zydus Lifesciences
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic…
-
8 months ago benzinga.com
Agenus Data From Phase 1b C-800-01 Study Evaluating Botensilimab Shows Survival With BOT+BAL Associated With Systemic Inflammation In Blood, Tumor Immune Activity Within Tumor Microenvironment
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced new translational and clinical biomarker data from its Phase 1b C-800-01 trial (NCT03860272) evaluating botensilimab (BOT), an…
-
8 months ago benzinga.com
Agenus To Highlight New Data At AACR-IO Exploring Systemic And Tumor Inflammation Biomarkers With BOT/BAL In Immunologically Cold Tumors
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted for…
9 months ago benzinga.com
Looking Into Agenus Inc's Recent Short Interest
Looking Into Agenus Inc's Recent Short Interest
-
9 months ago benzinga.com
Agenus Expands Global Medical Affairs Infrastructure And Early-Access Support Capabilities In Response To Increasing Physician-Initiated Interest Regarding Authorized Access To BOT+BAL
Medical Affairs scale-up supports France's multi-tumor AAC access framework and expanding paid named-patient programs requestsAgenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today…
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
11 months ago benzinga.com
Agenus Q3 EPS $1.94 Misses $1.98 Estimate, Sales $30.200M Miss $55.713M Estimate
Agenus (NASDAQ:AGEN) reported quarterly earnings of $1.94 per share which missed the analyst consensus estimate of $1.98 by 2.02 percent. This is a 162.99 percent increase over losses of $(3.08) per…
11 months ago benzinga.com
Earnings Scheduled For November 10, 2025
Earnings Scheduled For November 10, 2025
-
12 months ago benzinga.com
Insights Ahead: Agenus's Quarterly Earnings
Insights Ahead: Agenus's Quarterly Earnings
-
1 year ago benzinga.com
Agenus Releases New Data From Its botensilimab And balstilimab Combination Showing Durable Survival Benefits Across Multiple Late-Stage, Treatment-Resistant Cancers And That ~40% Of Patients With Very Limited Survival Expectation Are Alive At Two Years
Durable survival in heavily pretreated patients, including those who failed prior immunotherapy and with active liver metastasesSignals of tumor agnostic benefit observedTumor types included CRC,…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maintains $23 price target.
-
1 year ago benzinga.com
Agenus Says Investigational Combination BOT/BAL Now Available To Eligible Patients With Refractory MSS mCRC Under France's Compassionate Access Framework
Agenus Inc. (NASDAQ:AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maintains $23 price target.
-
1 year ago benzinga.com
Agenus to Host Aug. 27 Virtual Briefing Highlighting Cancer Drug Pipeline and Phase 3 CRC Study
Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will…